Kairos Pharma, Ltd.
KAPA
$0.34
-$0.02-5.28%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.71% | 6.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.43% | -1.39% | |||
| Operating Income | -19.43% | 1.39% | |||
| Income Before Tax | -21.17% | 2.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.17% | 2.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.17% | 2.36% | |||
| EBIT | -19.43% | 1.39% | |||
| EBITDA | -20.00% | 1.43% | |||
| EPS Basic | -20.15% | 5.35% | |||
| Normalized Basic EPS | -20.29% | 5.32% | |||
| EPS Diluted | -20.15% | 5.35% | |||
| Normalized Diluted EPS | -20.29% | 5.32% | |||
| Average Basic Shares Outstanding | 0.78% | 3.18% | |||
| Average Diluted Shares Outstanding | 0.78% | 3.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||